NovaDel receives Issue Notification from USPTO for oral spray

Dec 16 2009

NovaDel Pharma Inc. (NYSE AMEX: NVD), today announced that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a new U.S. Patent, No. 7632517, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaDel’s oral spray technology.

As previously announced, NovaDel’s Zolpimist ™ (zolpidem tartrate) 5 mg and 10 mg Oral Spray product is approved by the U.S. Food and Drug Administration (FDA) for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpimist is NovaDel’s second product approved by the FDA that uses NovaDel’s proprietary NovaMist™ oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien^®, the world’s leading sedative hypnotic for the treatment of insomnia.

NovaDel maintains an extensive worldwide portfolio of intellectual property rights for select compounds using its pioneering oral spray delivery system. With the issuance of this patent, the Company has been granted nine patents in the U.S., three patents in Canada and 66 patents throughout Europe, including Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, Spain, Sweden and Switzerland. Additionally, NovaDel has over 80 patents pending around the globe.